2Zhao R, Qiu A,Tsai E, et al. The proton-coupled folale transporter: impact on pometrexed transport and on antifolates activities compared with the reduced folate carrier[ J]. Mol Pharm, 2008,74 (3) :854- 862.
3Baldwin CM,Perry CM. Pemetrexed:a review of its use in the management d advanced non-squamous non-small cell lung cancer[J]. Drugs ,2009,69(16) :2279-2302.
5Celli AC, Rothbart SB, Heyer CL, et al. Therapeutics by cytotoxic metabolite accumulation:pemetrexed causes ZMP accumulation- AMPK activation and mammalian target or rapamycin inhibition[J]. Cancer Res,2009,69 ( 13 ) :5467-5474.
6Latz JE, Karlsson MO, Rusthoven JJ, et al. A semimechanistic-physiologic population Phannacokinetic/pharmacodynamlc model for neutropenia follow/ng pemetrexed therapy[ J]. Cancor Chemothor Pharmacol,2006,57 (4) :412-426.
7Gridelli C, Kaukel E, Gregore V, et al. Single-agent pemetrexed or sequential pemetrexed/gemcltabine as frontoline treatment of advanced non-small ceU lung cancer in elderly patients or patients ineligible for phase II platinum-based chemotherapy: a trial[J]. J Thorac Oneol,2007,2(3) :221-229.
8Tucker S. The role of pemetrexed in second-line chemotherapy for advanced non-small eel] lung cancer[J]. Curr Drug Targets ,2010, 11(1) :58-60.
9Secagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III stodies[J].Oncologist ,2009,14(3 ) :253-263.
10Ciuleanu T, Bwdowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomiseddot [ J]. Lancet,2009,374(9699) :1432-1440. 3 study.
